Response of tumour necrosis factor-alpha to delayed in vitro monocyte stimulation in patients with septic shock is related to outcome.
We hypothesized that cytokine production following delayed in vitro cell stimulation (to reproduce physiological cellular status at baseline) may be related to outcome in patients with septic shock. A total of 20 patients were included in a prospective clinical study, conducted in a medico-surgical intensive care unit in a university hospital. Blood samples were obtained at the onset of septic shock; these were treated to retain the cells, but to wash out autologous plasma (containing potential inflammatory stimuli such as cytokines, bacterial products and drugs) and replace it with foetal calf serum. Each treated sample was divided into two sets of four aliquots, to be stimulated either immediately or after an overnight period of resting incubation at 37 degrees C. The rest period was to allow recovery from potentially reversible endogenous or pharmacologically induced alterations in cellular response, in order to reproduce a near physiological state at baseline. In vitro cellular challenges used low-dose (0.2 ng/ml) or high-dose (1 ng/ml) CD14-dependent lipopolysaccharide and CD14-independent pokeweed mitogen to induce the production of tumour necrosis factor-alpha (TNF-alpha), and interleukins-1 beta and -10. Levels of TNF-alpha, interleukin-1 beta and interleukin-10 were significantly higher (P<0.05) when cell stimulation was delayed for 16 h, indicating a functional down-regulation of cells during septic shock. Moreover, TNF-alpha responses obtained with high-dose lipopolysaccharide were significantly greater in cells from patients who subsequently survived septic shock (n=13; median value 1392 pg/ml; range 592-2048 pg/ml) than in cells from non-survivors (n=7; median value 708 pg/ml; range 520-1344 pg/ml). These observations support the existence of individual differences in the inflammatory response that could influence patient outcome following septic shock.
Appoloni
Olivier
O
Department of Intensive Care, Erasme University Hospital, Route de Lennik 808, B-1070 Brussels, Belgium.
Vincent
Jean-Louis
JL
Duchateau
Jean
J
D000368:Aged; D002478:Cells, Cultured; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology; D011043:Pokeweed Mitogens / Q000494:pharmacology; D011446:Prospective Studies; D012772:Shock, Septic / Q000276:immunology*; D018709:Statistics, Nonparametric; D013268:Stimulation, Chemical; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D007375:Interleukin-1; D008070:Lipopolysaccharides; D011043:Pokeweed Mitogens; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10